Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus rhamnosus HM126
- Development stage
- Preclinical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus rhamnosus HM126 is a probiotic bacterial strain isolated from healthy human breast milk, currently under investigation for the treatment of allergic and inflammatory disorders, including atopic dermatitis and allergic rhinitis. As a live biotherapeutic product, it functions by modulating the gut-skin and gut-respiratory axes. The strain helps maintain the balance between type 1 (Th1) and type 2 (Th2) immune responses, leading to a reduction in inflammatory cytokines such as interleukin-4 (IL-4) and a decrease in immunoglobulin E (IgE) levels. Preclinical studies have demonstrated its ability to reshape gut microbiota composition and metabolites, resulting in reduced scratching frequency and skin lesion severity in atopic dermatitis models, as well as alleviation of nasal symptoms in allergic rhinitis.
- Other names
- L. rhamnosus HM126
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)FFAR3 (Free fatty acid receptor 3)FFAR2HDAC (HDAC family)PRR (Pattern recognition receptors)IgE (Immunoglobulin E)IL-4 (Interleukin 4)
Beyond the preview
Go deeper on lacticaseibacillus rhamnosus HM126.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus rhamnosus HM126.